Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.

Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.